On December 3, 2025, a complaint (Complaint) was filed in Delaware Court of Chancery that highlights the potential risks when a fund sponsor seeks to push through a continuation vehicle (CV) transaction over the objection of existing investors. Specifically, the Complaint alleged that the conflicted CV transaction would have benefitted the sponsor and its affiliates while simultaneously harming the existing investors. Further, several procedural concerns related to the CV transaction were alleged in the Complaint, including that the sponsor used coercive, “underhanded” tactics that violated its fiduciary duties.
Although the Delaware Court of Chancery promptly approved a stipulation to temporarily halt the CV transaction until at least the end of February 2026, contingent on an independent arbiter’s review of the facts, the Complaint illustrates risks that can arise in CV transactions. This article summarizes the Complaint and the alleged conflicts of interest in the CV transaction; considers the frequency of investor complaints and litigation in CV transactions; explores what alternative steps the sponsor could have reasonably taken to mitigate the risks; and offers key takeaways from legal experts interviewed by the Private Equity Law Report.
See “Secondaries Unlocked: A Market Grown Up and Continuing to Evolve” (Nov. 13, 2025); and “SEC Charges PE Sponsor With Improper Accelerated Monitoring Fees and Continuation Fund Transfer” (Dec. 14, 2023).
Overview of the Complaint
Background
The primary plaintiff in the proceeding is the Abu Dhabi Investment Council Company PJSC (ADIC), which is a leading sovereign wealth fund operating out of the United Arab Emirates and part of the approximately $300‑billion Mubadala investment group. The other co-plaintiffs listed in the Complaint – Imperial Infrastructure Investments and Portman Limited – are wholly owned by ADIC.
The primary defendant, Energy and Minerals Group LP (EMG), is a PE sponsor with approximately $13 billion of assets under management as of September 2024. EMG operates through the following affiliates, which are also named as co‑defendants in the Complaint:
- EMG Fund II GP, LP, which is the GP of Fund II Offshore, LP (Offshore II);
- EMG Fund III GP, LP, which is the GP of Fund III Offshore, LP (together with Offshore II, the Funds); and
- EMG Ascent Continuation Fund, LP (EMG CV).
In 2011, ADIC began investing in the Funds, and served as a member of the LP advisory committee (LPAC) of each fund. Starting in or around 2013, the Funds made investments in Ascent Resources (Ascent), a natural gas producer, through two vehicles. Through those investments, EMG came to acquire a sizable total share of Ascent, along with playing a central role in Ascent’s corporate governance.
Urgent CV Approval Timing
Minimum Notice
On October 23, 2025, EMG informed LPAC members of its intent to conduct a special joint meeting and LPAC vote to approve selling 30 percent of its stake in Ascent to the EMG CV. Although the timing of the announcement satisfied the minimum required notice – just five business days – in the Funds’ limited partnership agreements, that notice period was equal to or shorter than significantly less consequential events (e.g., 10‑business days’ notice for funding mandatory capital calls).
In ADIC’s view, the notification offered limited information about the CV deal, promising more information at some unspecified later date. For example, EMG failed to provide an FAQ document to investors until October 29, 2025, just one day before the LPAC meeting was set to take place. ADIC argued in the Complaint that EMG’s decision to provide material information about a conflicted transaction so soon before the scheduled vote denied LPAC members the time needed to weigh critical facts and come to an informed decision about the proposed deal.
Expedited LPAC Vote
In the Complaint, ADIC accused EMG of moving at a “relentless” pace in its pursuit of LPAC approval for the CV transaction despite the clear conflicts of interest involved. According to the Complaint, ADIC was candid about its concerns about EMG’s “inexplicable rush” to put the CV transaction to a vote during the meeting on October 30, 2025, arguing that it and other LPAC members needed more time and information.
In response, EMG stressed the urgency of closing the transaction by the end of 2025, leaving the parties “a very limited window of time to launch the election process.” In keeping with its rushed approach, EMG provided ADIC with a presentation and fairness opinion on October 27, 2025, just three days before the scheduled meeting, and was not forthcoming with its FAQ document until October 29, 2025. “This needlessly expedited timeline and belated disclosures were contrary to industry standards,” according to the Complaint.
During the joint special meeting on October 30, 2025, EMG reiterated the supposed urgency for the LPAC to approve the CV deal by November 1, 2025, a date not in keeping with earlier deadlines EMG had put forth. In addition, ADIC claimed that EMG “monopolized” the meeting through such tactics as limiting LPAC members’ questions for EMG to 20 minutes.
When voting on the CV transaction finally took place, EMG garnered only three approval votes from 43 LPAC members – failing to gain CV transaction approval – amid abstentions from a large majority of LPAC members, some of whom continued to stress the need for more time.
See our two-part series on the evolution of LPACs: “Trends Toward Robust Procedures and Accountability for LPAC Members” (Oct. 8, 2019); and “Grappling With GP and LPAC-Member Conflicts of Interest While Avoiding Liability” (Oct. 15, 2019).
Stifled Discussion Among LPAC Members
Concurrent with its alleged efforts to expedite the vote on October 30, 2025, ADIC alleged that EMG attempted to prevent LPAC members from meeting and deliberating about the merits of the CV transaction. An email sent out by EMG stated that “no one is authorized to discuss the . . . analysis at the pre-meeting and it is a violation of the non-reliance letter to do so.” In response, ADIC and other LPAC members requested that EMG coordinate an in‑camera session for LPAC members only to discuss the CV transaction. EMG refused that request – “in direct contravention of industry guidance,” according to ADIC – citing the supposed impossibility of transferring hosting rights for the virtual meeting to another attendee.
According to the Complaint, EMG also refused to facilitate discussion among LPAC members about the CV transaction even after the special vote on October 30, 2025. Arguing that a discussion among LPAC members would merely lead to “misinformation and mischaracterization,” EMG sought to funnel all discussions through itself as “the only ones that truly have the facts and all relevant and accurate information.” Further, ADIC alleged that EMG neglected to provide clarity about whether it would call for a new vote after additional requested information was shared.
As a result of those actions following the special vote on October 30, 2025, eight LPAC members, including ADIC, explicitly requested that EMG put off any further vote for 30 days, to allow for more informed deliberation about its merits. After ignoring the request for almost a week, EMG then denied it and stated that “the vote remains open.” According to the Complaint, EMG also sought to take advantage of leaving the voting process ambiguously open by attempting to engage with LPAC members – and share information with certain members – on a selective, individual basis.
See “How Good Governance Frameworks Can Optimize Outcomes in Continuation Funds” (Mar. 15, 2022).
Flawed Disclosures and Information to LPs
Beyond the timing and procedural issues associated with how EMG conducted the LPAC approval process for the CV transaction, ADIC also alleged that EMG delivered either erroneous information or omitted key facts altogether.
In its ongoing effort to seek information that might clarify the proposed CV transaction, ADIC claims it sought access, through multiple requests starting on October 30, 2025, to a virtual data room that EMG’s advisor had allegedly used to keep track of EMG’s efforts to secure CV investor commitments and close the transaction. On November 8, 2025, EMG offered LPAC members a slightly revised version of the FAQ and allowed ADIC – but not many other LPAC members – access to the data room.
According to the Complaint, ADIC’s review of the information in the data room raised concerns about material misstatements and omissions in EMG’s earlier disclosures about the CV transaction. Specifically, a pair of confidential information memoranda (CIMs) that EMG had prepared for potential CV investors in March 2025 and September 2025, respectively, allegedly contained information about Ascent’s valuation, and possible strategic alternatives, that contradicted the “bleak commentary” on Ascent that EMG provided in disclosures to LPAC members in advance of the special meeting.
Skewed Metrics in Valuations
The fairness opinion prepared for the CV transaction drew heavily on information provided by EMG, with ADIC raising particular questions about analysis provided as to Ascent’s “inventory life” – i.e., how long Ascent would be able to sell natural gas before depleting its supplies. According to the Complaint, Ascent’s valuation in the fairness opinion suffered from a lowball estimate of that metric, whereas a markedly more positive picture was presented to investors by Ascent on November 5, 2025.
Further, despite claims in the initial notice that a “headline” price would be available to investors that chose to cash out, EMG offered investors that cashed out a share price significantly discounted from EMG’s Q3 2025 net asset value calculations for Ascent shares. ADIC went on to allege in the Complaint that EMG made false claims that Ascent’s uncompetitive standing as compared to certain industry peers made the proposed CV transaction pricing fair.
Denial of Alternatives
In its communications with investors on October 27, 2025, EMG rejected alternatives to a CV transaction, describing an IPO, for example, as “not the immediate path to monetization” for the investors, involving a prolonged path to monetization, public market volatility risk and a likelihood that final valuations would be significantly lower than what investors could otherwise realize through the CV transaction.
To support its argument, EMG provided an expected net present value that would be “materially lower” than was realizable through the CV transaction, the Complaint details. ADIC alleged in the Complaint, however, that EMG sought to roll over a portion of its own capital into the CV while investing additional capital at an “artificially low” price, presumably in anticipation of a merger or IPO in the foreseeable future.
To support its stance, EMG cited an IPO by another company in the natural resources sector that did not turn out as hoped for investors, leading to a marked decline in the company’s share price. Further, EMG dismissed out of hand any other alternatives to the CV transaction, including gauging M&A interest from third parties or pursuing a direct sale of the Funds’ Ascent shares, the Complaint alleges.
Failure to Disclose Self‑Interest
Finally, ADIC alleged that EMG downplayed its own interest in the CV transaction. The lower- and higher-end exit multiples of EMG’s projected fees and returns after exiting the Ascent investment did not reflect the actual range based upon EMG’s own calculations, the Complaint details. EMG was allegedly evasive in its response to ADIC requests for exact calculations and provided outcome scenarios that did not correspond exactly to the “base case and upside case” breakdowns ADIC had requested.
“Together, these key disclosure violations rendered meaningless the safeguards that [LPs] had negotiated for by including the [LPAC] approval requirements in the fund documents,” the Complaint states.
Alleged LPAC Approval and Initiated Litigation
Approximately two weeks after the special vote by the LPAC on October 30, 2025, EMG allegedly notified investors that, without holding any additional meetings, the CV had been approved by a majority of the LPAC. On November 20, 2025, EMG circulated an election form to all investors providing them the right to sell or roll their respective fund interests into the new CV, which would reset the sponsor’s entitlement to carried interest at the new valuation.
In response, ADIC sent EMG several demands on November 24, 2025, including a request for arbitration that required a 45‑day waiting period under the terms of the fund’s governing documents. As part of ADIC’s demand for arbitration, they requested that EMG delay closing the CV transaction until arbitration could begin. The following day, on November 25, 2025, EMG allegedly responded by refusing to agree to ADIC’s requests.
In response, on December 3, 2025, ADIC initiated litigation in the Delaware Court of Chancery seeking an injunction to preserve the arbitrator’s ability to award effective relief. On December 4, 2025, EMG agreed with ADIC to delay closing of the CV until the arbitrator could issue a decision.
Key Takeaways
Although the actions and behavior described in the Complaint must be treated only as allegations, there are a number of practical takeaways for sponsors to consider as they undertake future CV transactions.
Practical Components of CV Deals
Scope of Information
The legal action against EMG underscores that GPs need to communicate with investors about the CV transaction over a reasonable time frame and in a transparent, consistent and fair-minded manner, in the view of Davis Polk partner Leor Landa. “There should be multiple touchpoints with LPs over the course of a CV transaction so the GP can explain its rationale, describe the parameters of the specific transaction and react to investor feedback.”
Based only on the actions described in the Complaint, “this matter reinforces the notion that regular and transparent communication is a hallmark of a good CV transaction,” Landa reasoned. “If you would rather do a CV transaction than an M&A sale or an IPO, you have to be able to articulate the reasons,” he added. “Being transparent and forthcoming with investors also has the benefit of mitigating both legal and commercial execution risks, the latter by giving GPs an opportunity to assess sales volume and clearing price.”
In the circumstances, it would have been prudent for EMG to present itself to investors as available and approachable, Landa stated. The GP would have been well-advised to organize an executive session with investors as and when needed, and to convey a message to the effect of, “If you have questions about the deal, we are the ones who have the answers, and we need to be in the room to help answer your questions.”
Equitable Disclosures to All Investors
Transparent and nonselective communications (i.e., communications that reach all investors rather than a selective subset) of the rationale for a CV transaction should be an obvious step for GPs, and its absence here is notable, agreed King & Spalding partner Daniel Daneshrad. The importance of that approach applies not only to communication between EMG and investors, but also to communication among investors. “The Complaint illustrated how, from ADIC’s point of view, EMG was very selective in the notifications and disclosures that it provided, and discouraged people from talking to each other about the deal,” he observed.
Instead of using the many opportunities available in the time before the projected closing of the CV transaction, EMG allegedly followed up on the disappointing results of the LPAC vote – where only 3 out of 43 LPAC members voted in favor of the CV transaction – by making minor concessions to individual investors and seeking to win them over, a strategy that violated the GP’s duty to treat investors equitably. “CV transactions are ‘conflicted’ by nature,” noted Winston & Strawn partner Scott Naidech. “As a result, you always need to be mindful that you’re running a fair process and abiding by your contractual and fiduciary duties to all your stakeholders.”
According to the Complaint, EMG also showed prospective new investors a data room full of information about what coming into the Funds entailed, but didn’t provide that same information to existing investors that EMG was going to force to choose between rolling and selling, Daneshrad pointed out. “I tell my clients, ‘Disclose to your existing and your incoming investors the same information about the product you’re asking (or forcing) them to invest in.’”
See “SEC 2026 Examination Priorities Highlight Classic Compliance Issues, Retailization Efforts and AI Oversight” (Jan. 8, 2026); and “Practical Insights on Five Problematic GP/LP Dynamics Identified by SEC Chair Gensler” (Feb. 1, 2022).
Fair CV Deal Process
The responsibility to communicate equitably with all existing and prospective investors places special burdens on GPs to run a fair and transparent CV process.
“For that to happen, you need to make all appropriate disclosures to your LPs and LPACs at the right times, and ensure you or your advisors are answering all their questions and keeping them informed about the process,” Naidech summarized. “LPAC approval is often a cornerstone to getting conflicts waived and moving forward with the deal, so it’s crucial to have consistent outreach with your LPAC, inform them about the process and ensure they’re on board,” he emphasized.
“Down the road, if an investor wants to be a squeaky wheel and complain about the price or the transaction, then the GP can say, ‘Well, we ran a fair process to get the best result,’” Naidech continued. To prove the fairness of a GP’s CV process, he noted that it is helpful if they can point to a variety of steps taken along the way, including that they:
- worked with the LPAC to get its approval;
- hired an independent financial advisor;
- obtained a fairness opinion from a third party; and
- solicited and vetted bids from potential investors.
Completing each of those measures can lend credibility to GP claims that they picked the best offer, and pursued the optimal process, with their existing LPs’ best interests in mind.
Further, it is worth noting that prospective investors in CV transactions can be another “force for good” in ensuring that GPs run sound CV deal processes, Landa added. “CV transactions are an area where buyers and advisors tend to impose good processes, even if sponsors do not do so naturally,” he reflected. “Buyers and advisors do not want to be involved in deals where there are allegations of a bad process, as that type of negative publicity does not help anyone – buyers, sponsors or advisors.”
See “SBAI Introduces New Standards and Accompanying Guidance on Valuing Illiquid Assets” (Apr. 3, 2025).
Rarity of Litigation
In view of the different parties’ shared interest in a successful process, and the ongoing utility of CV transactions, Landa finds it unlikely that the litigation between EMG and ADIC will encourage similar legal actions. “CVs are wonderful tools, and we expect their popularity to grow,” he summarized. “If there is anything to learn here, it is that we need to make sure we are really focused on the process, transparency and rationale for CV deals.”
In fact, stepping back from the EMG matter, it is important to remember that LP-driven lawsuits against GPs over CV deals are still a relatively rare phenomenon, Landa noted. “Complaints are rare, because GPs are usually careful to run a fair process, get their LPAC on board and get appropriate conflict waivers,” Naidech agreed. “If you follow market practices, you should be able to vet problems early on and deal with them.”
The level of communication between GPs and their investors – and the space that gives GPs to work through issues and questions with their investors – is usually sufficient to avoid the kind of outcome seen in the EMG matter, Landa noted. “Usually, there are a lot of opportunities for LPs to raise issues and for GPs to react to them and to contextualize and explain issues,” he observed. “So when an LP does raise a complaint – which is not particularly common – the GP can work through that issue, while also ensuring investors feel their voices are heard and their concerns are understood.”
Echoing that point, Daneshrad asserted that although it is common for investors to ask questions about CV transactions, LP complaints typically only arise when GPs fail to answer those types of questions. “In fact, LPs’ questions tend to be very much along the lines of those that ADIC and its affiliates repeatedly posed and that EMG did not answer to their satisfaction,” he said.
See “Inflection Points in Negotiating PE Fund Core Economic Terms and Structuring GP-Entity Carry Allocations to Incentivize Employees” (Aug. 4, 2020).
Alignment of GP‑LP Interests
It would be a mistake to portray the EMG matter as somehow representative of deeper problems in the CV market, or the attitudes and behavior of GPs that lead CV transactions. Instead, in many cases, LPs have been, and continue to be, the beneficiaries of such transactions, with strong protections rooted in their origins, Landa stated. CV transactions were originally introduced for assets acquired before, and devalued during, the global financial crisis of 2008, with CV processes implemented in those difficult circumstances to ensure that LPs were given the best possible choices and not being coerced into something bad.
By contrast, the CV market today typically centers on trophy assets that are being sold at attractive prices, with a lot more participants in the market to vet pricing and terms, Landa continued. “Although CV deals are better now, the basic scaffolding that GPs and their lawyers built back then to protect investors in tough circumstances remains, even as the market has evolved and innovated,” he reasoned. “Most CV transactions these days go very smoothly, and given the broad lack of liquidity in the markets, we are seeing very high sales volume. LPs are typically happy to participate and receive liquidity.”
Instead, the EMG matter serves as a helpful reminder to the PE industry that people pay attention to deal terms, no matter how prevalent CV transactions have become, Daneshrad asserted. “But that is healthy, because a lot of the transactions are sound and take place for a very real structural reason: ever since the Sarbanes‑Oxley Act and the Dodd‑Frank Act, the public markets have become less popular and companies want to stay private for longer, which CV transactions facilitate.”
See “Continuation Vehicles Survey Highlights Increasing Convergence of Some Terms, Vicissitudes Among Others” (May 29, 2025).
